29 completed, 2 recruiting, 2 terminated. 23 Phase 1, 5 Phase 2, 5 Phase 3.
By phase and status
Follow seltorexant: new trials by email Literature Review of seltorexant trials Research Report on seltorexant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Seltorexant, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | 600 | 2026-04-30 | 2026-11-03 |
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) - Depressive Disorder, Major | Phase 3 | Recruiting | 752 | 2024-07-25 | 2026-11-03 |
A Study of Seltorexant in Participants With Probable Alzheimer's Disease
Seltorexant, Placebo - Alzheimer Disease | Phase 2 | Completed | 88 | 2022-05-19 | 2025-04-27 |
A Study of JNJ-42847922 (Seltorexant) in Healthy Participants
Seltorexant - Healthy | Phase 1 | Completed | 10 | 2022-02-03 | 2025-04-27 |
A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
Suvorexant, Zolpidem, Seltorexant - Healthy Non-dependent, Recreational Sedative Users, Abuse Potential | Phase 1 | Completed | 127 | 2021-12-17 | 2025-04-27 |
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy
Seltorexant, Placebo - Depressive Disorder, Major | Phase 1 | Terminated | 31 | 2021-09-02 | 2025-04-27 |
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
JNJ-42847922 - Healthy, Hepatic Impairment | Phase 1 | Completed | 24 | 2021-08-05 | 2025-04-27 |
A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants
JNJ-42847922 - Renal Impairment | Phase 1 | Completed | 24 | 2021-03-31 | 2025-04-27 |
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
Seltorexant, Placebo - Depressive Disorder, Major | Phase 3 | Completed | 588 | 2020-09-16 | 2026-05-12 |
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Seltorexant, Matching placebo to Seltorexant, Quetiapine XR - Depressive Disorder, Major | Phase 3 | Completed | 757 | 2020-09-15 | 2025-08-13 |
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Seltorexant, Placebo - Depressive Disorder, Major | Phase 3 | Terminated | 212 | 2020-09-15 | 2025-06-04 |
A Study of Seltorexant in Healthy Participants
Seltorexant - Healthy | Phase 1 | Completed | 69 | 2020-09-14 | 2025-04-27 |
A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder
Seltorexant Dose 1, Seltorexant Dose 2, Placebo - Depressive Disorder, Major | Phase 1 | Completed | 63 | 2020-07-16 | 2025-04-27 |
A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea
Seltorexant 40 mg, Placebo - Sleep Apnea, Obstructive | Phase 1 | Completed | 34 | 2019-01-04 | 2025-04-27 |
A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants
Seltorexant High Dose, Seltorexant Low Dose - Healthy | Phase 1 | Completed | 151 | 2018-10-01 | 2025-04-27 |
A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants
Seltorexant, Placebo Matched to Seltorexant, Placebo Matched to Moxifloxacin - Healthy | Phase 1 | Completed | 52 | 2018-04-09 | 2025-04-27 |
A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions
Seltorexant 40 mg, Seltorexant 20 mg - Healthy | Phase 1 | Completed | 49 | 2018-02-09 | 2025-04-27 |
A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder
JNJ-42847922 20mg, JNJ-42847922 40mg, Placebo - Depressive Disorder, Major | Phase 1 | Completed | 140 | 2018-01-05 | 2025-04-27 |
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR - Depressive Disorder, Major | Phase 2 | Completed | 107 | 2017-12-12 | 2025-04-29 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder
Placebo, JNJ-42847922, 5 mg, JNJ-42847922, 10 mg - Insomnia Disorders | Phase 2 | Completed | 365 | 2017-11-23 | 2025-04-29 |
Showing 20 of 33. Sign in to see all of them.
Conditions studied
Depressive Disorder, Major (12) · Sleep Initiation and Maintenance Disorders (3) · Alzheimer Disease (1) · Renal Insufficiency (1) · Sleep Apnea, Obstructive (1)
Sponsors
Janssen Research & Development, LLC (27) · Janssen-Cilag International NV (4) · Janssen Cilag N.V./S.A. (1) · Janssen Pharmaceutical K.K. (1)
Countries
United States (22) · Germany (10) · Belgium (7) · Netherlands (6) · Argentina (4) · Bulgaria (4) · Poland (4) · Brazil (3) · Czechia (3) · Japan (3) · Malaysia (3) · Russia (3) · Slovakia (3) · Spain (3) · Ukraine (3)
Results publications
PMID 29848147, PMID 34324636, PMID 39663378, PMID 40802194, PMID 41795948
NIH funding
2014 (3), 2015 (3), 2017 (3), 2016 (1), 2019 (1), 2023 (1)